Bio/Pharma Business

Portfolio swaps between Novartis and GSK involve oncology, vaccines, and consumer products.

Sun Pharma acquisition of Ranbaxy Laboratories will create the fifth-largest specialty generics company in the world.

The I'm In campaign is designed to increase participation by diverse patient populations for clinical trials.

Crystal Pharmatech selects Freeslate for its CM Protege PharmD System.

Lilly Diabetes supports the American Diabetes Association for the seventh year in a row.

Croda receives two achievements in relation to EXCiPACT.

MedImmune and AstraZeneca enter a three-year collaboration with the Clinical and Translational Science Institute at the UC San Francisco.

AbbVie launches art initiative designed to explore impact of chronic inflammatory diseases.

Thirteen companies are accepted for participation in the supply chain program.

Novartis is named among the 2014 Corporate Knights Global 100.

AstraZeneca completes the acquisition of the entirety of BSM's interests in the companies' diabetes alliance.

Vanda Pharmaceuticals receives approval from FDA for Hetlioz for the treatment of Non-24.

AbbVie will open its first manufacturing facility in Singapore.

Thermo Fisher Scientific outlines new business segments with acquisition of Life Technologies.

Pharmaceutical companies are adopting multiple choice partnership strategies to meet the challenges of today's R&D instead of being focused primarily on internal development.

With numerous biologics set to come off patent soon and the percentage of new therapeutics based on biomolecules growing, demand for contract manufacturing in the biopharma space is heating up.

AstraZeneca and Bristol-Myers Squibb Diabetes Alliance provides a $5 million grant to the American Diabetes Association.

Competition seeks to encourage academic research and accelerate drug delivery applications.

In 2013, the EMA's Committee for Medicinal Products for Human Use recommended 81 medicines for human use for marketing authorization, compared with 57 in 2012.

Generics, market dynamics, and global demand are changing drug spending patterns.

Janssen's donation program will improve access to the company's approved HIV medicines for children and adolescents in sub-Saharan Africa.

Former US President Jimmy Carter and Pfizer commemorate the 15th anniversary of the International Trachoma Initiative to end blinding trachoma by the year 2020.

The Bristol-Myers Squibb Foundation is awarding 10 grants to fund programs for veterans and their families.

Almost 400 new medicines for infectious diseases, including viral infections, bacterial infections, fungal infections and parasitic infections.

GDUFA is off to a good start from a facility inspection perspective, but there are storm clouds on the horizon.

Jill E. Sackman, D.V.M., PhD, senior consultant at Numerof & Associates, Inc. discusses the market forces impacting biopharmaceutical manufacturing

Pharmaceutical Technology takes a look at the major deals and moves of 2013.

A roundup of developments in global health and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Global spending on medicines is expected to meet the $1 trillion threshold in 2014 and reach $1.17 trillion by 2017, according to a recent report by the IMS Institute for Healthcare Informatics

Legislators agree on a limited bill affirming FDA authority over compounders while setting up a process for national drug tracking.